We conducted a prospective phase II trial utilizing the CliniMACs system to perform CD34 þ -cell selection of PBSCs from haploidentical donors to evaluate engraftment and hematoimmunological reconstitution. In total, 21 children with hematological malignancies or nonmalignant conditions underwent conditioning with 1200 cGy TBI, thiotepa, fludarabine and Thymoglobulin. Patients received megadoses of CD34 þ cells (median: 22 Â 10 6 /kg) with a fixed dose of 3 Â 10 4 /kg CD3 þ cells/kg, and engraftment occurred in 90% with prompt recovery of neutrophils and platelets. Grade II acute GVHD (aGVHD) was seen in 32% (95% confidence interval (CI), 15-54%) of evaluable patients, there was no grade III-IV aGVHD, and chronic extensive GVHD was seen in 35% (95% CI, 17-59%) of patients. The estimated 2-year EFS was 62% (95% CI, 48-83%) with a median survivor follow-up of 49 months (range: 18-119 months). Patients with nonmalignant diseases had an estimated 2-year EFS of 100% (95% CI, 56-100%) and patients with malignancies in remission had an estimated 2-year EFS of 56% (95% CI, 22-89%). Megadose CD34 þ cells with a fixed CD3 þ cell dose from haploidentical related donors resulted in good outcomes for pediatric patients with nonmalignant diseases and those with malignant diseases transplanted in remission.
INTRODUCTION
Many children lack an HLA-matched donor for use in allogeneic hematopoietic cell transplantation (HCT). Two alternative donor options exist for these patients: mismatched unrelated umbilical cord blood (UCB), or a haploidentical relative. An advantage of haploidentical HCT is the opportunity for post-transplant cellular therapy. However, the use of haploidentical donors is limited by three factors: (1) major HLA barriers must be overcome to prevent graft rejection and achieve engraftment; (2) stringent T-cell depletion is required to limit severe GVHD; and (3) delays in functional immune reconstitution has led to high rates of infection and relapse. 1, 2 We performed haploidentical related-donor HCT in children utilizing a platform of myeloablative conditioning with megadoses of CD34 þ cells, which has been shown to overcome barriers to engraftment and accelerate recovery of neutrophils and immunity. 3, 4 This approach is associated with severe immunodeficiency and infections soon after transplant. We addressed the profound T-cell depletion that occurs with the CliniMACs CD34 þ -cell selection system 5 by adding back a fixed CD3 þ -cell dose to the stem cell product hypothesizing that this would be associated with low rates of GVHD while promoting engraftment. We also reduced the dose of Thymoglobulin used in the conditioning regimen hypothesizing that the added T cells would prevent graft rejection. Delays in post-HCT immune reconstitution could then be managed via the use of small doses of donor lymphocytes infusions (DLI), 6 which have been shown to improve recovery of normal T-cell numbers. 6, 7 To test these hypotheses, we prospectively enrolled 21 pediatric patients with high-risk diseases in a phase II trial evaluating the CliniMACs machine to prepare CD34 þ -selected cells from haploidentical related-donors, with a primary endpoint of successful engraftment.
MATERIALS AND METHODS

Patients and donors
Eligible patients for the prospective trial presented to the University of California San Francisco Benioff Children's Hospital or the University of North Carolina from March 2002 to July 2010 with a malignant or nonmalignant disease in need of an allogeneic HCT, and who lacked an HLA-identical related, X9/10 HLA-allele-matched unrelated or X5/6 HLAallele-matched cord blood donor with an adequate cell dose. Patient and donor characteristics are described in Table 1 . Two patients were initially enrolled on trial, but were later deemed ineligible owing to receipt of non-protocol conditioning. They were excluded from the analysis, and replacement patients were enrolled. The median patient age was 6.4 years (range: 1.4-20.5 years). Patients were considered to be in CR at transplant only if markers of minimal residual disease status (when possible for that disease) were negative. The transplant protocol was approved by the Institutional Review Boards of both institutions, and informed consent was obtained from the donors and the patient/parents in accordance with the Declaration of Helsinki.
shielding, plus 50% shielding of the brain and eyes in patients with nonmalignant diseases), 5 mg/kg/dose thiotepa every 12 h for two doses (day À 6), 40 mg/m 2 /dose of fludarabine once daily (days À 6 to À 2). The major modifications were increasing and fractionating the dose of TBI (from 800 cGy) and reducing the dose of rabbit anti-thymocyte globulin (ATG; Thymoglobulin; 0.5 mg/kg on day À 5, then 1 mg/kg/dose on days À 4 to À 2), to a total of 3.5 mg/kg from 6 mg/kg, the latter to improve post-HCT immune reconstitution. Patients received no posttransplant GVHD prophylaxis.
Donor PBSC collection and manipulation
High-resolution typing was performed at HLA-A,-B, -C, -DRB1 and -DQB1 (except as noted). Killer-cell immunoglobulin-like receptor (KIR) typing and natural killer-cell alloreactivity were not routinely tested, but alloreactivity based on recipient and donor HLA Cw typing was analyzed retrospectively and donors were considered able to exert donor-vs -recipient natural killer-cell alloreactivity when the recipient did not possess one HLA-C allele group (C1 or C2) present in the donor. 8 Beginning on day À 5 of conditioning, donors received 8 doses of granulocyte CSF (G-CSF) subcutaneously (5 mcg/kg/dose) every 12 h for 4 days. 9 On day À 1, donors underwent apheresis, collecting X5 Â 10 10 mononuclear cells. Two to four additional doses of G-CSF were administered if the donor required additional collections on day(s) 0 (and þ 1). CD34 þ cells were selected using the CliniMACs (MiltenyiBiotec, Bisley, UK) System. CD34 þ cells were counted utilizing a phycoerythrinconjugated mAb against CD34 and a FITC-conjugated mAb against CD45, then run on a FACScan flow cytometer (Becton-Dickinson, San Jose, CA, USA). 7-Amino-actinomycin D was added so that gating was performed on only viable cells based on the ISHAGE method. 10 The targeted CD34 dose was X20 Â 10 6 /kg of recipient body weight, though this was not always achieved ( Table 1 ). The CD3 dose was 3 Â 10 4 /kg. The CD34-positive cells were tested for T cells utilizing a phycoerythrin-conjugated mAb against CD3. If the CD3 count was below the goal dose, then CD3 þ cells were added from the CD34-negative fraction. The added-back T cells were not tested for functionality. The protocol lead investigator (MJC) and two co-investigators (C-YO and EAD) analyzed the initial laboratory methodology at both institutions to ensure that comparable levels of CD34 þ and CD3 þ cells were administered.
Infection prophylaxis, monitoring and definitions of immune recovery T-cell reconstitution was defined as an absolute CD4 count X0.2 Â 10 9 /L and a PHA response X50% of the lower limit of normal control. Prophylaxis was given against Candida spp. infections with fluconazole (3-6 mg/kg/day) and against Pneumocystis jirovecii with cotrimoxazole (5 mg/kg/day of trimethoprim component divided twice daily for 3 consecutive days per week) until T-cell reconstitution. All patients received acyclovir three times per day (500 mg/m 2 /dose by mouth, maximum 800 mg; 250 mg/m 2 /dose intravenously ) for herpesvirus prophylaxis from day 0 until T-cell reconstitution. All patients received IVIG (400 mg/kg) every 3 weeks until the immunoglobulin M was 40.5 g/L and the isohemagglutinin titers were X1:8.
11 Patients then received killed vaccines, followed by testing for specific antibody responses and lymphocyte proliferation to tetanus. Positive results allowed patients to receive live vaccines. 12 CMV screening, originally by antigen, and later by PCR was performed weekly until discharge and then every 1-2 weeks until T-cell reconstitution, with any level considered positive (lower limit of detection for PCR ¼ 1000 copies/mL). EBV PCR was obtained every 2 weeks until 3 months post HCT. Human herpes virus-6 and adenovirus were screened for by PCR in symptomatic patients.
Donor lymphocyte infusions
DLI were prospectively prepared from the CD34-negative fraction by cryopreserving aliquots of 10 Â 10 4 CD3 þ cells/kg. At the 12-week evaluation, if the absolute CD4 count was o0.1 Â 10 9 /L and there was no evidence of active GVHD, an infusion of 3 Â 10 4 cryopreserved donor CD3 þ cells/kg was performed. Infusions were repeated at 4-week intervals until the absolute CD4 count was 40.1 Â 10 9 /L, providing there was no GVHD. Earlier infusion of DLI was permitted in the setting of falling donor chimerism or persistent viral infection on antiviral therapy, and these could be repeated every 4 weeks until improvement. Subsequent DLI doses could be escalated (4-6 Â 10 4 CD3 þ cells/kg) if the patient had previously tolerated, but did not appear to respond, to the lower dosage.
Statistics and definitions
The primary endpoint of the trial was durable engraftment, with a goal of X90%. We determined that a sample size of 21 patients was required to estimate the 95% confidence interval (CI) of the engraftment rate based on binomial approximations with the lower bound of 65.5%, and we closed the trial once that sample size was accrued. Donor engraftment was measured by analysis of short tandem repeats, as described previously, 13 beginning approximately 1 month post HCT and continuing monthly for the first year. The 2-year EFS, OS and relapse incidence (RI) were estimated by the Kaplan-Meier method using log-rank tests (SPSS 16.0, Chicago, IL, USA). Events were defined as graft failure, relapse/progressive disease or death. Non-relapse mortality (NRM) was defined as any cause of death other than relapse or progressive underlying disease. Immune reconstitution data were censored at the time of relapse. Acute (a) and chronic (c) GHVD following HCT and DLI were graded using standard criteria. /L for 3 consecutive days) occurred in 90% of patients (95% CI, 70-99%) at a median time of 13 days (range: 9-15 days). Engrafted patients all had high-level donor chimerism (X95% donor whole blood) at first measurement, with the exception of a chemotherapy-naive patient with juvenile myelomonocytic leukemia (UPN 17), who progressed o2 months post HCT. The two patients who failed to engraft both had acute myeloblastic leukemia. Both underwent a second transplant; one successfully engrafted, but died of progressive disease over a year later (UPN 6), and one died of CMV infection (UPN 4). In the engrafted patients, primary platelet recovery (X50 000 Â 10 9 /L without transfusion for 7 days) occurred at a median of 16 days (range: 12-19 days).
Immune reconstitution In total, 12 patients received X1 DLI, per protocol either for a CD4 count o0.1 Â 10 9 /L at 12 weeks post HCT (n ¼ 5), a persistent viral infection (n ¼ 5) or falling chimerism (n ¼ 2). Seven patients required one DLI, two patients received two DLI and three patients received more than or equal to4 DLI. One patient (UPN 14) received experimental CMV-specific T cells. 16 The median time to a CD4 count of 40.2 Â 10 9 /L was 5.2 months (range: 0.9-12 months), excluding three patients who died before reaching this level. There was a trend toward lower CD4 counts in deceased patients, especially 46 months post HCT, which also highlighted the greater need for DLI in this group, reflecting the poorer immune reconstitution in the group that eventually expired ( Figure 1 ). The median time to a PHA of X50% of control was 7.9 months (range: 4.6-15 months), excluding 6 patients who died before reaching this level. All patients that eventually reached a PHA of 450% of control survived long term. Three patients took 49 months to reconstitute T cells, and all had experienced either aGVHD and/or cGVHD ( Table 2) 
GVHD
Grade I-II aGVHD was seen in 47% (9/19; 95% CI, 27 À 68%) of evaluable patients, including 3 patients who developed aGVHD following DLI. Grade II aGVHD was seen in 32% (6/19; 95% CI, 15-54%) of evaluable patients. There were no cases of grade III-IV aGVHD. cGVHD was seen in 35% (6/17; 95% CI, 17-59%) of evaluable patients, two with limited skin involvement and four with extensive multi-organ involvement, including two patients who developed extensive cGVHD following DLI, both of whom died of infection while on immunosuppressive treatment. The other four patients resolved their cGVHD, with a median time to stopping all immunosuppression of 12 months (range, 6-26 months).
NRM and other complications
In the engrafted patients, infections were very common, with 26% (95% CI, 12-50%) developing Gram-negative rod bacteremia, 11% (95% CI, 2-33%) developing invasive fungal infections and 58% (95% CI, 36-77%) demonstrating viremia with one or more double-stranded DNA viruses ( Table 2 ). All cases of CMV viremia following initial HCT were not associated with CMV disease. Two patients developed EBV-related post-transplant lymphoproliferative disease, which were treated with rituximab and DLI and resolved completely before their deaths from other causes. In addition, there was one case of autoimmune hemolytic anemia and two cases of thrombotic thrombocytopenic purpura, all of which resolved. The day 100 NRM was 5% (95% CI, 0-24%), due to disseminated CMV disease following primary graft failure and attempted second HCT. The 2-year estimated NRM was 17% (95% CI, 4-36%), as two additional patients died of infectious causes (disseminated mucormycosis and bacterial sepsis) while receiving immunosuppressive treatment for cGVHD. There were no cases of noninfectious mortality.
Relapse
The 2-year RI was 37% (95% CI, 15-59%). In total, 5 of 15 patients with a hematological malignancy relapsed or had evidence of progressive disease at a median of 3.7 months (range: 1.1-12.4 months) post HCT ( Table 2 ). Three of five relapsed patients underwent a second haploidentical HCT, but all five expired from progression of their underlying disease. The numbers were too small to detect any difference in RI between patients receiving an HCT from a maternal donor (2/6 patients relapsing) vs a paternal donor (2/3 patients) or nonparental donor (1/6 patients). Similarly, most patient-donor pairs did not possess predicted natural killercell alloreactivity, and the impact of natural killer alloreactivity upon RI was unevaluable.
Survival
The median follow-up of survivors was 49 months (range: 18-119 months). The 2-year EFS (21 patients) was 62% (95% CI, 40-83%). The 2-year OS was identical to the EFS. Patients transplanted for a nonmalignant disease (N ¼ 6) had 2-year EFS of 100% (95% CI, 56-100%; Figure 2 ). Patients transplanted for a malignant disease had a 2-year EFS of 47% (95% CI, 21-73%), with a 2-year EFS of 56% (95% CI, 22-89%) if transplanted in remission (N ¼ 9), but only a 33% 2-year EFS (95% CI, 9-72%) if transplanted with evidence of active disease (N ¼ 6; p ¼ 0.085).
DISCUSSION
The concept of utilizing a haploidentical related-donor has been a standard practice for many years following a non-myeloablative conditioning regimen for patients with severe combined immunodeficiency disease, where the timing of the HCT is urgent. 4, 17, 18 However, combining CD34-selected haploidentical cells with a fully myeloablative conditioning regimen for patients with malignancy has been more fully explored in adult patients, 1,2 though some pediatric reports exist. [19] [20] [21] Fewer reports have focused on children with life-threatening nonmalignant diseases, [21] [22] [23] where the use of UCB stem cells predominates because many children are an appropriate size to receive the small cell dose in an UCB unit. For larger children and adults, two UCB units can be combined. However, this approach has been associated with increased GVHD without apparent improvement in engraftment, 24 a suboptimal outcome for patients with nonmalignant diseases. Although a relatively small number of patients was included in this trial, the use of CD34-selected cells from a haploidentical related-donor is associated with similar rates of primary engraftment (90%) to than seen following double UCB transplants (86-93%). 24, 25 Furthermore, neutrophil recovery appeared faster with haploidentical HCT (median ¼ 13 days, range: 9-15 days) when compared with double UCB transplants (median ¼ 23-25 days). 24, 25 Platelet engraftment was also rapid following haploidentical HCT (median ¼ 16 days, range: 12-19 days).
Although haploidentical HCT has been associated with slow immune recovery, in our study the median time to recovery of CD4 cells to 40.2 Â 10 9 /L was 5.2 months, and a median normal (450% control) PHA response was seen at 7.9 months. These are comparable to a median of 6-12 months in UCB transplant recipients, 26 though faster rates of CD4 recovery can be seen in UCB recipients when ATG is omitted from the conditioning, albeit at a risk of GVHD. 27 It is conceivable that similar hastening of immunological recovery may be possible in haploidentical recipients with further modifications of the ATG dosing. Furthermore, grade II-IV aGVHD rates are relatively comparable between the two stem cell sources: 32% for haploidentical recipients vs 19-37% for a single-UCB unit and 48% for double UCB units, with less risk of grade III-IV GVHD in haploidentical recipients in our trial and other reports. 24, 26, 28 Conversely, there appears to be slightly more cGHVD in the haploidentical setting (35%) when compared with single-(0-20%) or double-(18%) UCB units, 24, 26, 28 though most cases resolved promptly. Similarly, the NRM incidence following haploidentical HCT (17%) was lower than that seen following receipt of single-(20-26%) or double-(29%) UCB units. 24, 26 However, the RI in our haploidentical cohort was 37%, higher than that reported after single-(20-34%) or double-(19%) UCBT, 24, 26, 28 though this varies depending on how many patients with advanced disease are included in a study. More aggressive add-back of T cells may be necessary to decrease RI after haploidentical HCT, especially for patients not in remission.
The EFS seen following haploidentical HCT for treatment of a malignant disease was 47%, comparable to that reported following single-(40-50%) or double-(51%) UCB transplants. 24, 26, 28 Our data suggest that both approaches provide similar transplant outcomes, a conclusion also reached by other groups. 19 Leung et al. 20 also demonstrated that, for children with acute leukemia, modern haploidentical HCT provides similar outcomes to both matched sibling and unrelated donor HCTs. Their results, in combination with ours and others, 19, 21 suggest that haploidentical HCT should be more widely utilized for patients with otherwise incurable diseases. One situation where haploidentical transplant may be preferable over cord blood is when attempting posttransplant immune manipulation via DLI to reduce relapse 29 or treat opportunistic infections. 30, 31 The high numbers of cells that can be harvested from a haploidentical donor greatly facilitates this process, while attempts to do this with UCB may require utilization of additional units. 32 Two novel aspects of this trial were the decreased dose of ATG compared with prior trials of haploidentical HCT and the use of a fixed CD3 dose. Less ATG did not appear to affect engraftment rates, which were similar in this trial (90%) and the Perugia trial (93%). 1 This appeared to shorten the delayed T-cell recovery, as ATG remains in the blood for up to 28 days after T-cell replete HCT 33 and higher doses appear associated with opportunistic infections. 34, 35 Modulation of this may ultimately depend on individualized dosing of ATG, as significant interpatient variability exists in its elimination. 33 The fixed T-cell dose was used because the CliniMACs is very efficient at depleting T cells, however, the final T-cell dose in the stem cell product still varies from patient to patient.
1 By fixing the T-cell dose for all patients, we eliminated this variable and in the future will be able to evaluate the role of other factors, such as the composition of the infused CD3 cells (CD4, CD8 and CD25/foxp3), KIR ligand incompatibility 8 and the use of a maternal donor, 36 on the development of GVHD, immune reconstitution and relapse prevention. Other groups have shown that fixed T cell add-backs are feasible after CD34 selection of unrelated donor hematopoietic cells, though post-HCT pharmacological immunosuppression was also given. 37, 38 With this prospective trial, we have established at our centers the utility of haploidentical related-donor HCT for the treatment of children with both nonmalignant and malignant diseases (in remission). At our centers, haploidentical relatives are considered the stem cell source of choice for patients with diseases only curable with HCT and without an HLA-identical related, X9/10 HLA-allele-matched unrelated or X5/6 HLA-allele-matched cord blood donor with an adequate cell dose. However, the outcomes for patients with malignant diseases not in a deep remission, such as juvenile myelomonocytic leukemia or chemotherapy-refractory acute leukemias, were less optimal. Until improvements can be made in augmenting the GVL effect, these patients may need to accept the risks associated with an 8/10 unrelated or 4/6 cord blood donor. One modification that we will make will be to replace TBI with melphalan, for patients with nonmalignant diseases, as melphalan will likely be associated with a lower rate of some long-term complications, an important consideration for this young patient population. Another will be to begin to augment the cellular composition of the re-infused cells. Although our results are encouraging for patients in remission, a more robust graft-vs-leukemia effect is needed, especially for those patients not in remission at the time of HCT. In this trial, we attempted to deal with this via the use of delayed preemptive DLIs. Although this strategy was reasonably safe, some patients developed GVHD and some relapsed. One strategy for dealing with this would be to infuse a dose of regulatory T cells around the time of transplant, allow them to expand and then attempt higherdose preemptive DLIs. 39 In a mouse model, this has been shown to abrogate GVHD without affecting the GVL activity. 40 These modifications should continue to improve the outcomes of pediatric patients undergoing haploidentical HCT, thereby increasing the options and availability of HCT for patients without matched donors.
